## ABSTRACT

## CRF ANTAGONISTIC PYRAZOLO[4.3-B]PYRIDINES

This invention concerns compounds of formula

$$\mathbb{R}^4 \xrightarrow{\stackrel{\mathbb{N}}{\hat{\mathbb{N}}}} \mathbb{N} \mathbb{R}^2$$
 (I),

10

20

25

5

including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein R1 is C1-6alkyl, NR5R6, OR6 or SR6; R2 is C1-6alkyl, C1-6alkyloxy, or C1-6alkylthio; R3 is Ar1 or Het1; R4 is hydrogen or C1-6alkyl; R5 is hydrogen, C1-8alkyl, mono- or di(C3-6cycloalkyl)methyl, C3-6cycloalkyl, C3-6alkenyl, hydroxyC<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkylcarbonyloxyC<sub>1-6</sub>alkyl, mono- or di(C<sub>1-6</sub>alkyl)amino-C1-6alkyl or C1-6alkyloxyC1-6alkyl; R6 is C1-galkyl, mono- or di(C3-6cycloalkyl)methyl. Ar<sup>2</sup>C<sub>1-6</sub>alkyl, Ar<sup>2</sup>oxyC<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxyC<sub>1-6</sub>alkyl, hydroxyC<sub>1-6</sub>alkyl, C<sub>3-6</sub>alkenyl, thienylmethyl, furanylmethyl, tetrahydrofuranylmethyl, C1\_6alkylthioC1\_6alkyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, di(C1-6alkyl)amino, or C1-6alkylcarbonylC1-6alkyl; or R5 and R6 taken together with the nitrogen atom to which they are attached may form a pyrrolidinyl, piperidinyl, homopiperidinyl, morpholinyl, or thiomorpholinyl group, optionally substituted with 1 or 2 substituents each independently selected from C1-6alkyl or C1-6alkyloxyC1-6alkyl; and and Ar1 and Ar2 are each optionally substituted phenyl; and Het! is optionally substituted pyridinyl; having CRF receptor antagonistic properties; pharmaceutical compositions containing such compounds as active ingredients; methods of treating disorders related to hypersecretion of CRF such as depression, anxiety, substance abuse, by administering an effective amount of a compound of formula (I).